This is a past TAG meeting and is part of our history of presenting exciting companies and technologies.
February Meeting -- Friday, February 24, 2012 07:00 AM
What: "Vermillion: You Can't Cure the Disease Until You Can Diagnose It ."
Who: Gail Page, CEO
Austin's burgeoning biotech scene can be typified by its ability to quickly and successfully bring bioscience from university labs to the market. Vermillion is working with institutions like Johns Hopkins, M.D. Anderson, and Stanford to discover biomarkers for a variety of unmet clinical needs. They have created or are creating novel diagnostics for such diseases as Ovarian Cancer and Peripheral Arterial Disease. Here Gail Page, Vermillion's CEO, will give an intriguing story of how her company is commercializing breakthrough science from across the country.
Meeting Agenda
7:00 AM to 7:30 AM – Networking and Breakfast
7:30 AM to 7:45 AM – Announcements and Introductions
7:45 AM to 8:30 AM – Presentation with interchange
Where: The Austin Club, 110 East 9th Street (a half a block east of Congress on 9th Street).
Breakfast is $20 with reservations ($19 if prepaid before reservation deadline) and $25 without reservations.
About the Program
Proteomics is the scientific study of proteins, particularly their structures and functions. Vermillion, harvests the discoveries of leading medical research institutions to develop and commercialize novel high-value diagnostic tests to better diagnose, monitor and treat diseases. The company has programs in oncology, hematology, cardiology and women's health. Its first test, OVA1®, is the first FDA-cleared blood test for pre-surgical cancer diagnosis of ovarian tumors. In recent clinical trials, OVA1 correctly identified 70% of cancers missed by current methods.
Vermillion was founded in 1997 in Fremont, California as Abiotic Systems (but changed its name in 2007). The company relocated to Austin in September 2010 "to take advantage of Austin's strong talent pool and cost-effective environment."
Ms. Page, Vermillion's CEO, joined Vermillion in 2004. During her tenure she has successfully raised over $110 million in funding. Prior to Vermillion, Ms. Page was Executive VP and COO of Luminex. She has held senior level management positions with Laboratory Corporation of America, the second leading diagnostics testing company in the U.S., in such assignments as Senior VP, Office of Science and Technology, head the Cytology and Pathology Services, and chair of the company's Scientific Advisory Board. Ms. Page has Medical Technology and Associates Science degrees from the University of Florida. She has completed an Executive Management course at Northwestern's Kellogg School.
This program is a continuing part of TAG's focus on innovative new technology based businesses that provide a glimpse of the area's economic future. Entrepreneurs: TAG's program presents case studies in how to start, sustain and become successful. Come to TAG to meet people who are following the entrepreneurial path.
Future Events
TAG March Meeting, March 30, 2012:
InView: Bringing the Spectrum Down to Size (and Cost) With Bob Bridge, CEO
InView Technology's innovative computational imaging technology can provide cameras that take pictures across the spectrum, taking pictures that "see" more than the unaided human eye or night vision goggles can. The company is commercializing science discovered at Rice University and will revolutionize the world of sensors.
|
|
